EGFR and neoplasm: Given the upregulation of HER3 in resistance to EGFR- or HER2-targeted therapy, the use of HER3-targeted monotherapy or combination strategies has been suggested to overcome acquired resistance mechanisms and augment tumor inhibition [108,110].